AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25226843
Drug: Doxorubicin-eluting bead-transarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-eluting bead-transarterial chemoembolization (DEB TACE) combined with systemic sorafenib (400 mg twice a day)
Trial: 9622285
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (ethyl esters) 2 g/day
Trial: 2970456
Drug: Sertraline 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 400 mg
Trial: 25986018
Drug: High-dose DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DHA (0.86%) and AA (0.91%) supplementation
Trial: 25986018
Drug: High-dose DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DHA and AA supplementation
Trial: 23601026
Drug: Levofloxacin-containing sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin-containing sequential therapy (LCS)
Trial: 23601026
Drug: Levofloxacin-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin-containing quadruple therapy (LCQ)
Trial: 20498324
Drug: PA-824 200
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PA-824 200 mg daily
Trial: 20498324
Drug: PA-824 600
RxNorm normalized name: OMS-824
DrugBank: OMS-824 (DB17874)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA-824 600 mg daily
Trial: 20498324
Drug: PA-824 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA-824 1,000 mg daily
Trial: 20498324
Drug: PA-824 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA-824 1,200 mg daily
Trial: 20498324
Drug: Standard antituberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antituberculosis treatment
Trial: 8227460
Drug: Didanosine (DDI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (DDI) 375 mg twice daily for 4 days
Trial: 8227460
Drug: Didanosine (DDI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (DDI) 375 mg twice daily for 4 days with Ketoconazole (KET) 200 mg daily for 4 days
Trial: 8227460
Drug: Ketoconazole (KET)
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole (KET) 200 mg daily for 4 days
Trial: 2979066
Drug: Anesthetic doses
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetic doses of fentanyl (46 +/- 1.3 micrograms/kg) and oxygen (group I)
Trial: 2979066
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of fentanyl (3 to 4.7 micrograms/kg; mean = 3.54 +/- 0.1 micrograms/kg) + etomidate (0.4 mg/kg) intravenously (IV) (group II)
Trial: 29697768
Drug: NDV-3A vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDV-3A vaccine (1 intramuscular dose)
Trial: 26832428
Drug: Topical 90%
RxNorm normalized name: phenol topical 90% compounding liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 90% medical‐grade kanuka honey and 10% glycerine applied twice daily for 12 weeks after washing with antibacterial soap.
Trial: 26832428
Drug: Antibacterial soap
RxNorm normalized name: QSR Antibacterial Soap Product
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibacterial soap (Protex, triclocarban‐based) applied twice daily for 12 weeks.
Trial: 25070094
Drug: Artesun‐Plus (fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesun‐Plus (fixed-dose combination of artesunate and amodiaquine)
Trial: 12475453
Drug: Intravenous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enoxaparin (0.5 mg/kg)
Trial: 12475453
Drug: Intravenous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enoxaparin (0.5 mg/kg) with eptifibatide
Trial: 7795721
Drug: Minoxidil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minoxidil (1 ml, 2% solution)
Trial: 7795721
Drug: Nitroglycerine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine (2.5 g, 10% ointment)
Trial: 798582
Drug: Clozapine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (300 mg per day)
Trial: 25957224
Drug: Clopidogrel-aspirin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-aspirin therapy
Trial: 29112701
Drug: Docetaxel treatment
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel treatment for <6 cycles
Trial: 29112701
Drug: Docetaxel treatment
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel treatment for 6 cycles
Trial: 29112701
Drug: Docetaxel treatment
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel treatment for >6 cycles
Trial: 23467946
Drug: HTS 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTS 5% bolus (125 cc every 6 hrs, N: 11)
Trial: 23467946
Drug: HTS 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTS 5% infusion (500 cc for 24 hrs, N: 12)
Trial: 23467946
Drug: Mannitol 20%
RxNorm normalized name: mannitol 20% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 20% (1 g/kg bolus, repeated 0.25‐0.5 g/kg every 6 hrs for 3 days, N: 10)
Trial: 2407911
Drug: Non-treatment for
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment for alcohol abuse
Trial: 26780348
Drug: Δ9-THC (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ9-THC (all doses)
Trial: 10942184
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pentoxifylline at 1000 hours
Trial: 10942184
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pentoxifylline at 2200 hours
Trial: 10942184
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pentoxifylline (both treatments)
Trial: 16988209
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg)
Trial: 1616168
Drug: Ranitidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (100 mg)
Trial: 3895761
Drug: Bepridil 200
RxNorm normalized name: bepridil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil 200 mg/day
Trial: 6362386
Drug: Bepridil 300
RxNorm normalized name: bepridil 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil 300 mg/day
Trial: 3895761
Drug: Bepridil 400
RxNorm normalized name: bepridil 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil 400 mg/day
Trial: 20345546
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 50 microg once daily into each nostril for 3 months
Trial: 20345546
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray once daily into each nostril for 3 months
Trial: 15877290
Drug: High-dose growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose growth hormone (GH) administration for 4 hours
Trial: 15877290
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GH administration)
Trial: 12544508
Drug: Irbesartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (angiotensin II type 1 receptor blocker)
Trial: 12544508
Drug: Atenolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta 1-adrenergic receptor blocker)
Trial: 11827617
Drug: Cognitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive and behavioral treatment including education about memory loss, relaxation training, memory skills training, and cognitive restructuring for memory-related beliefs.
Trial: 8526782
Drug: Nifedipine oros
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine oros 30 mg/day
Trial: 8526782
Drug: Nifedipine oros
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine oros 60 mg/day (for non-responders)
Trial: 2191779
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine (0.2 mg daily)
Trial: 2191779
Drug: Oral captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral captopril (122.9 mg daily)
Trial: 2191779
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine and Oral captopril
Trial: 31170680
Drug: Hépar (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hépar (1 L daily for 14 days)
Trial: 31170680
Drug: Low-mineral water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-mineral water (1 L daily for 14 days)
Trial: 25982590
Drug: Intravenous carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous carbamazepine (administered at 70% of the oral dosage, mean 675.1 mg) infused over 30 min
Trial: 25982590
Drug: Intravenous carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous carbamazepine (administered at 70% of the oral dosage, mean 675.1 mg) infused over 15 min
Trial: 25982590
Drug: Intravenous carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous carbamazepine (administered at 70% of the oral dosage, mean 675.1 mg) with rapid infusions (2-5 min)
Trial: 25982590
Drug: Oral carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral carbamazepine (mean 962.5 mg)
Trial: 15166555
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion of 25 ng.kg(‐1).min(‐1)
Trial: 15166555
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion of 50 ng.kg(‐1).min(‐1)
Trial: 15166555
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion of 100 ng.kg(‐1).min(‐1)
Trial: 15166555
Drug: Propofol in
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol in combination with remifentanil
Trial: 3277912
Drug: Triamterene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene (50 mg)
Trial: 3277912
Drug: Oxprenolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (160 mg)
Trial: 3277912
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chlorthalidone and triamterene
Trial: 27188814
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg DHA/day (3 capsules daily)
Trial: 22409211
Drug: Ivabradine 7.5
RxNorm normalized name: ivabradine 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine 7.5 mg twice daily for 5 days
Trial: 15916852
Drug: Incorrect *G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incorrect *G condition (e.g., He happened using it)
Trial: 15916852
Drug: Incorrect *I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incorrect *I condition (e.g., He postponed to use it)
Trial: 15531473
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment at 1 or 2 mg GH/m² body surface.d (approximately 0.035 or 0.07 mg/kg.d)
Trial: 3924084
Drug: High-dose alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alfentanil anaesthesia (150 micrograms kg‐1 initially, followed by continuous infusion at a rate of 3 micrograms kg‐1 min‐1)
Trial: 3924084
Drug: Neurolept anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurolept anaesthesia (droperidol 0.25 mg kg‐1 plus fentanyl 5 micrograms kg‐1 initially, followed by intermittent incremental doses of fentanyl 50 micrograms)
Trial: 3924084
Drug: High-dose alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alfentanil anaesthesia
Trial: 2455132
Drug: verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil (120 mg b.i.d.)
Trial: 2455132
Drug: nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (20 mg b.i.d.)
Trial: 31439812
Drug: Niraparib 100
RxNorm normalized name: niraparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 100 mg
Trial: 31439812
Drug: Niraparib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib (all doses)
Trial: 21317163
Drug: Trial interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial interventions (subject involvement, weekly phone reminders, routine counselling)
Trial: 16525107
Drug: Ethionamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethionamide (250 mg or 500 mg, six times a week)
Trial: 16525107
Drug: Prothionamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothionamide (250 mg or 500 mg, six times a week)
Trial: 16525107
Drug: Ethionamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethionamide (500 mg)
Trial: 16525107
Drug: Prothionamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothionamide (500 mg)
Trial: 16525107
Drug: Prothionamide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothionamide (both dose levels)
Trial: 10217586
Drug: 23-valent PS
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent PS vaccine (control group)
Trial: 370178
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic 1
Trial: 370178
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic 2
Trial: 370178
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic 3
Trial: 26220149
Drug: Individualized dose
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dose of rapid‐acting insulin (2 ± 1 units, range 0‐4 units) administered immediately after resistance exercise
Trial: 26220149
Drug: No insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No insulin administered after resistance exercise
Trial: 12680735
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg pergolide (D1/D2 receptor agonist)
Trial: 12680735
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg bromocriptine (D2 receptor agonist)
Trial: 7042030
Drug: Injection site
RxNorm normalized name: Dual Injection Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection site in the arm
Trial: 7042030
Drug: Injection site
RxNorm normalized name: Dual Injection Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection site in the abdomen
Trial: 30518425
Drug: Audencel (dendritic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audencel (dendritic cell-based immunotherapy)
Trial: 24333009
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg orally every day for 5 years
Trial: 20363596
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of 3.0 mmol of magnesium-chloride per kilogram of body weight in SES and SCS groups
Trial: 20363596
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of 3.0 mmol of magnesium-chloride per kilogram of body weight in SES group
Trial: 8775244
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg mifepristone + 0.5 mg gemeprost
Trial: 8775244
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mifepristone + 1.0 mg gemeprost
Trial: 1615873
Drug: Flecainide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (300 mg) as a single oral loading dose
Trial: 1615873
Drug: Amiodarone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (5 mg/kg as an intravenous bolus, followed by 1.8 g/day)
Trial: 6528619
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of heparin
Trial: 6528619
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of heparin
Trial: 27359058
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg (post-antiestrogen)
Trial: 27359058
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg (post-aromatase inhibitor)
Trial: 16446681
Drug: Bolus treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus treatment (1,000 ml of water immediately before exercise)
Trial: 16446681
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment (250 ml of water immediately before exercise and 250 ml at minutes 15, 30, and 45)
Trial: 11874392
Drug: Levormeloxifene 20-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levormeloxifene 20-160 mg
Trial: 11874392
Drug: Levormeloxifene 2.5-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levormeloxifene 2.5-320 mg (single doses)
Trial: 11874392
Drug: Levormeloxifene 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levormeloxifene 160 mg (multiple dosing)
Trial: 8039625
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with 6 MU of interferon alfa-2a, three times weekly for 9 months (group 1)
Trial: 8039625
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy with 6 MU of interferon alfa-2a for two 3-month cycles separated by a 6-month pause (group 2)
Trial: 8039625
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (group 1)
Trial: 8039625
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy (group 2)
Trial: 31899948
Drug: Water containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water containing 1.8375 × 10^10 cfu/l of probiotics for 8 weeks
Trial: 25535142
Drug: Intracoronary tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary tirofiban administration
Trial: 22339984
Drug: Self-help manual
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-help manual with standard care and treatment
Trial: 12074792
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia injection for repeat biopsy
Trial: 26954319
Drug: DFD‐01 (0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFD‐01 (0.05% betamethasone dipropionate in emollient spray)
Trial: 25136645
Drug: Standard advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard advice on medical nutrition therapy (Control)
Trial: 20608142
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml 2% lidocaine
Trial: 20608142
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml 2% mepivacaine
Trial: 15482535
Drug: lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamivudine 100 mg/day for up to 5 years
Trial: 9661540
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg during sternotomy and 30 mg/kg during initiation of cardiopulmonary bypass)
Trial: 18363032
Drug: Fluvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (20 mg daily)
Trial: 2123367
Drug: Moclobemide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (100 mg, 6 weeks)
Trial: 2123367
Drug: Imipramine (33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (33 mg, 6 weeks)